|
17 Dec 2020 |
CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV
|
|
16 Dec 2020 |
Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
|
|
16 Dec 2020 |
Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
|
|
16 Dec 2020 |
The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma
|
|
14 Dec 2020 |
Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2
|
|
14 Dec 2020 |
Codagenix and Serum Institute of India Announce Commencement of First-in-Human Trial of COVI-VAC, A Single Dose, Intranasal Live Attenuated Vaccine for COVID-19
|
|
14 Dec 2020 |
ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate
|
|
12 Dec 2020 |
Update on The University of Queensland COVID-19 vaccine
|
|
12 Dec 2020 |
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19
|
|
11 Dec 2020 |
European CHMP Adopts Positive Opinion for HEPLISAV-B®, Dynavax's Two Dose Adult Hepatitis B Adjuvanted Vaccine
|
|
11 Dec 2020 |
V2ACT Therapeutics™, LLC Announces FDA Clearance of an IND Application to proceed with a Phase 1/2a Study of V2ACT for the Treatment of Pancreatic Cancer
|
|
11 Dec 2020 |
City of Hope Now Enrolling Patients for Phase 1 Type 1 Diabetes Investigational Vaccine Trial
|
|
11 Dec 2020 |
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.
|
|
11 Dec 2020 |
ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
|
|
11 Dec 2020 |
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
|
|
10 Dec 2020 |
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents
|
|
10 Dec 2020 |
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine
|
|
09 Dec 2020 |
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older
|
|
08 Dec 2020 |
AZD1222 Oxford Phase III trials interim analysis results published in The Lancet
|
|
08 Dec 2020 |
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability
|
|
08 Dec 2020 |
Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine
|
|
08 Dec 2020 |
INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
|
|
08 Dec 2020 |
Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
|
|
06 Dec 2020 |
Providence Therapeutics Submits Clinical Trial Application (CTA) to Health Canada for the mRNA COVID vaccine
|
|
04 Dec 2020 |
IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
|
